Does semaglutide maintenance therapy change eating behavior enough to affect public health?

How does semaglutide actually change what and how people eat?

Semaglutide works by mimicking a natural hormone (GLP-1) that signals fullness to the brain and slows stomach emptying. But the key behavioral change is that it reduces hunger and alters food preferences—not just by making people eat less, but by changing what they crave. In a study of 32 Japanese adults with type 2 diabetes and obesity, those on semaglutide showed significant reductions in preferences for sweet and non-sweet carbohydrates (like white rice and noodles) and non-sweet fats (like high-fat snacks), while their desire for protein and fiber stayed the same [4]. This means the drug targets the very foods that drive obesity and metabolic disease.

Another study using the Control of Eating Questionnaire found that after 32 weeks on semaglutide, patients reported low levels of hunger and good control over their eating [3]. In a two-year study of four patients with hypothalamic obesity (a condition marked by extreme hunger), emotional eating scores dropped by 44 points (on a 0–100 scale) and uncontrolled eating scores dropped by 27 points, with patients reporting in interviews that they felt less hungry, more self-confident, and more productive [1]. These changes are not just about willpower—they reflect a biological shift in how the brain responds to food cues.

Can individual changes in eating behavior add up to a public health impact?

Yes, because the eating behavior changes semaglutide produces—reduced hunger, fewer cravings for calorie-dense foods, and better control over eating—are exactly the patterns that, if widespread, could lower obesity rates and related diseases like type 2 diabetes and hypertension. In the two-year study, patients lost a median of 16% of their body weight, and their HbA1c (a measure of blood sugar control) dropped by 6.4 mmol/mol, while LDL cholesterol fell by 0.5 mmol/L [1]. These are clinically meaningful improvements that, if replicated across millions of users, could reduce the population burden of cardiovascular disease and diabetes.

However, the public health impact depends on more than just efficacy. The studies here show that semaglutide is well-tolerated—side effects are mostly mild gastrointestinal symptoms [1][5]—but adherence can be an issue. One review notes that gastrointestinal side effects like nausea and vomiting can affect treatment adherence [5]. Also, the behavioral changes are not automatic: a study in mice found that weight loss from semaglutide happens in distinct phases, with different effects on food intake and energy expenditure over time [6], suggesting that individual responses vary. For public health to benefit, the drug needs to be accessible, affordable, and used consistently—which remains a challenge given current costs and the need for long-term treatment.

Could changing eating behavior with semaglutide have any downsides for public health?

The main concern is that any intervention that reduces food intake could, in some individuals, tip into disordered eating. However, the evidence here does not show that semaglutide triggers eating disorders. In fact, the opposite appears true: patients report better control over eating, not worse [3]. One study specifically looked at weight stigma and eating behavior in the general population and found that weight stigma itself is linked to disordered eating, comfort eating, and alcohol use [2]. By reducing weight and improving eating control, semaglutide might actually break that cycle for some people.

That said, the studies here are relatively short-term (most are 6 months to 2 years) and involve specific populations—people with type 2 diabetes, hypothalamic obesity, or schizophrenia. We don't yet have long-term data on whether these behavioral changes persist for decades or whether they could mask or trigger other issues. For example, a study on calorie labeling in menus found that while it led to lower-calorie choices, it did not immediately increase disordered eating risk, but the authors caution that longer-term effects are unknown [7]. Similarly, semaglutide's effects on eating behavior need to be studied over longer periods and in more diverse populations to fully understand the public health balance.

About These Sources

This answer is built on 7 peer-reviewed studies — published from 2021 to 2026, 5 from 2024 or later, 2 in Q1 journals, collectively cited 149 times — selected as the most relevant from 13 studies that passed quality screening, drawn from 69 papers retrieved from a database of over 500 million.

Sources used in this answer

Related research questions